Our Gene Therapy HTIA includes market insights and dynamics, detailed sector and sub-sector descriptions, and companies differentiated by se

Our 3D Bioprinting HTIA includes market insights and dynamics, detailed sector and sub-sector descriptions, and companies.

Brooks Hill Partners has invested in Cellbricks, a 3D bioprinting company transforming pharmaceutical research and clinical care.

Brooks Hill Partners has joined early-stage financing for Macula Vision Systems, a company focused AI-driven clinical microscopy.

Brooks Hill Partners has invested in Cake, an end-of-life planning and advanced care decision-making platform.

Brooks Hill Partners has announced an investment in Totient, an AI-driven biotech company focused on tertiary lymphoid structures.

Brooks Hill Partners announces an investment in the Seed financing of Qulab, a quantum computing company focused on molecular drug design.

Brooks Hill Partners has invested in Deep 6 AI, a company bringing AI technology to clinical trial recruitment.

Brooks Hill Partners has announced a new investment in reflect, a teletherapy company providing mental health services built for everyone.

Brooks Hill Partners continues to grow their portfolio by investing in Calibrater Health, a company building healthcare workflow automation.

Brooks Hill Partners has added Astrocyte Pharmaceuticals, a drug development company focused on brain injuries, to their portfolio.

Brooks Hill Partners invests in Wasabi, a startup specializing in high-capacity data archiving cloud services.

Brooks Hill Partners kicks off their healthtech portfolio with an investment in 3Derm Systems, who are focused on 3D imaging in dermatology.